Fritsche, Jens

Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing

Yadav, M., Jhunjhunwala, S., Phung, Q. T., Lupardus, P., Tanguay, J., Bumbaca, S., Franci, C., Cheung, T. K., Fritsche, J., Weinschenk, T., et al. (2014) · Nature

vaccines and immunoinformatics approachesCancer Immunotherapy and Biomarkers

Cited by 1,186

Actively personalized vaccination trial for newly diagnosed glioblastoma

Hilf, N., Kuttruff-Coqui, S., Frenzel, K., Bukur, V., Stevanović, S., Gouttefangeas, C., Platten, M., Tabatabai, G., Dutoit, V., van der Burg, S. H., et al. (2019) · Nature

Glioma Diagnosis and TreatmentImmunotherapy and Immune Responses

Cited by 938

Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy

Dutoit, V., Herold-Mende, C., Hilf, N., Schoor, O., Beckhove, P., Bucher, J., Dorsch, K., Flohr, S., Fritsche, J., Lewandrowski, P., et al. (2012) · Brain

Immunotherapy and Immune Responsesvaccines and immunoinformatics approaches

Cited by 201

Changes of the plasma metabolome during an oral glucose tolerance test: is there more than glucose to look at?

Zhao, X., Peter, A., Fritsche, J., Elcnerova, M., Fritsche, A., Häring, H.-U., Schleicher, E. D., Xu, G., & Lehmann, R. (2009) · American Journal of Physiology-Endocrinology and Metabolism

Metabolomics and Mass Spectrometry StudiesDiet, Metabolism, and Disease

Cited by 170

Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial

Wermke, M., Araujo, D. M., Chatterjee, M., Tsimberidou, A. M., Holderried, T. A. W., Jazaeri, A. A., Reshef, R., Bokemeyer, C., Alsdorf, W., Wetzko, K., et al. (2025) · Nature Medicine

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 73